Torrent Pharmaceuticals Ltd (TORNTPHARM) Q1 FY27 Results Analysis: EBITDA Margin Expands 130 bps, Revenue Surges 17%

Torrent Pharmaceuticals Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 4,921.00 Cr (+54.80% YoY) and PAT growth of +3.30% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Base business revenue grew 17% YoY, ahead of the 10-15% guidance, and consolidated EBITDA margin expanded 130 bps YoY to 33.8%. The JB Pharma acquisition delivered a 35.3% EBITDA margin, well above the guided 28-29% range, indicating faster-than-expected synergy realization. However, PAT growth was muted at 3.3% due to elevated finance costs and depreciation, and Germany business continued to decline 24% YoY due to supply disruption.

Key Investment Insights

Key Positives

• Base business revenue grew 17% YoY to Rs.3,720 Cr, ahead of the 10-15% guidance band.
• Consolidated EBITDA margin expanded 130 bps YoY to 33.8%, the highest in reported periods.
• JB Business EBITDA margin improved to 35.3% from 28.8% in Q1 FY26, beating the guided 28-29% range.
• India base business grew 19% YoY, outpacing IPM growth of ~12%, indicating market share gains.
• Net worth more than doubled to Rs.17,848 Cr due to the JB Pharma amalgamation, improving debt/equity from 1.76x to 0.82x.

Risk Factors

• PAT to owners grew only 3.3% YoY despite revenue growth of 54.8%, as finance costs (Rs.305 Cr, +444.6% YoY) and D&A (Rs.593 Cr, +195.0% YoY) from the JB acquisition absorbed incremental revenue.
• Germany business (Others) declined 24% YoY to Rs.112 Cr due to persistent supply disruption, continuing for third consecutive quarter.
• Other income remained negative at Rs.(12) Cr due to net foreign exchange losses, adding to margin pressure.
• Finance costs increased 444.6% YoY and 29.2% QoQ, reflecting the full quarter's interest on acquisition debt.